Human ENT1 peptide (ab48606)
Key features and details
- Purity: > 90% HPLC
- Suitable for: Blocking
Description
-
Product name
Human ENT1 peptide -
Purity
> 90 % HPLC. -
Accession
-
Animal free
No -
Nature
Synthetic -
-
Species
Human
-
Specifications
Our Abpromise guarantee covers the use of ab48606 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
Applications
Blocking
-
Form
Liquid -
Additional notes
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
- If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
- Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
- Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
- Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use. -
Concentration information loading...
Preparation and Storage
-
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
General Info
-
Alternative names
- Equilibrative NBMPR-sensitive nucleoside transporter
- equilibrative nitrobenzylmercaptopurine riboside (NBMPR)-sensitive nucleoside transporter
- Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter
see all -
Function
Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs). -
Tissue specificity
Expressed in heart, brain, mammary gland, erythrocytes and placenta, and also in fetal liver and spleen. -
Sequence similarities
Belongs to the SLC29A transporter family. -
Post-translational
modificationsGlycosylated. -
Cellular localization
Basolateral cell membrane. Apical cell membrane. Predominantly localized in the basolateral membrane in polarised MDCK cells. - Information by UniProt
Images
-
All lanes : Anti-ENT1 antibody (ab48607) at 2 µg/ml
Lane 1 : Human heart tissue lysate - total protein (ab29431)
Lane 2 : Human brain tissue lysate - total protein (ab29466)
Lane 3 : Human heart tissue lysate - total protein (ab29431) withHuman ENT1 peptide (ab48606) at 2 µg/ml
Lane 4 : Human brain tissue lysate - total protein (ab29466) withHuman ENT1 peptide (ab48606) at 2 µg/ml
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Performed under reducing conditions.
Exposure time: 4 minutes
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (0)
ab48606 has not yet been referenced specifically in any publications.